ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0088

Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review

Andre Ribeiro1, Larissa Dullius2, Andre Azeredo2, Laura Coates3, Odirlei Monticielo2, Charles Kohem2, Penelope Palominos2 and Natalia Sartori1, 1Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, 2Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 3Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom

Meeting: ACR Convergence 2022

Keywords: Access to care, Health Care, Psoriatic arthritis, quality of care, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Healthcare Disparities in Rheumatology Poster

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: In 2020, the International League of Associations for Rheumatology (ILAR) recommendations for management of psoriatic arthritis (PsA) were published. It aimed to adapt GRAPPA and EULAR recommendations to resource-poor settings. At that time, the paucity or absence of clinical studies endorsing the management of PsA patients in Latin America (LATAM) was remarked on by the international working group. Despite several challenges faced by patients and physicians in resource-poor countries, the literature on this theme is scarce. Our objective was to recognize the main challenges on the management of PsA in LATAM described in recent publications.

Methods: A systematic literature review (SLR) of clinical trials reporting at least one challenge/difficulty on the management of PsA in LATAM was conducted following PRISMA statements. References published in PubMed, Embase, and LILACS between 1980 and 2020 were included. The selection of references was conducted independently by two researchers in the Rayyan QCRI program. Data were independently extracted by two reviewers. The Cochrane tool was used to assess the quality of studies. All challenges were noted and categorized into domains. Data analysis was descriptive.

Results: The search strategy resulted in 1505 references. Fifteen studies (13,859 patients) were included in the final analysis: most were performed in Brazil (86.6%, N=13), recruited patients on biological therapy (80%, N=12) and were observational studies (100%, N=15). Difficulties faced by PsA patients and physicians were the high incidence of opportunistic infections (described in 46.6% of publications, N=7), non-adherence to therapy (20%, N=3), discordance between patients and physicians regarding remission rates (13.3%, N=2), low drug persistence (13.3%, N=2), limited access to DMARDs (13.3%, N=2), issues related to the storage of biological drugs (13.3%, N=2), elevated cost of biological drugs (13.3%, N=2), limited access to medical care (6.6%, N=1) and diagnostic delay (6.6%, N=1).

Conclusion: The challenges in the management of PsA in Latin America go beyond the care of opportunistic infections: special attention should be paid to logistical questions (e.g., correct medication storage, access to drugs and medical care) and educational problems (e.g., importance of adherence, patients understanding of disease and therapy). A research agenda focused on the idiosyncrasies of treatment in Latin America, which go beyond the classic clinical features and dive into cultural and economic facets, should be devised to better understand and to tailor new guidelines for this region of the globe.

Supporting image 1

Supporting image 2


Disclosures: A. Ribeiro, None; L. Dullius, None; A. Azeredo, None; L. Coates, AbbVie, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb (BMS), Eli Lilly, Gilead, Galapagos, Janssen, Medac, Novartis, Pfizer, UCB, Celgene, Biogen, Moonlake, GlaxoSmithKlein (GSK); O. Monticielo, None; C. Kohem, None; P. Palominos, None; N. Sartori, None.

To cite this abstract in AMA style:

Ribeiro A, Dullius L, Azeredo A, Coates L, Monticielo O, Kohem C, Palominos P, Sartori N. Challenges in the Management of Psoriatic Arthritis in Latin America: A Systematic Review [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/challenges-in-the-management-of-psoriatic-arthritis-in-latin-america-a-systematic-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/challenges-in-the-management-of-psoriatic-arthritis-in-latin-america-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology